Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И.Разумовского» Минздрава России. 410012, Россия, Саратов, ул. Б.Казачья, д. 112
Список исп. литературыСкрыть список 1. Delay J, Deniker P. Drug-induced extrapyramidal syndromes. Handbook Clinl Neurol 1968; 6: 248–66. 2. Berman BD. Neuroleptic Malignant Syndrome. A Review for Neurohospitalists. Neurohospitalist 2011; 1 (1): 41–7. 3. Волков В.П. Злокачественный нейролептический синдром (обзор современной иностранной литературы). Психиатрия и психофармакотерапия. 2010; 6: 28–34. / Volkov V.P. Zlokachestvennyi neirolepticheskii sindrom (obzor sovremennoi inostrannoi literatury). Psychiatry and Psy-chopharmacotherapy. 2010; 6: 28–34. [in Russian] 4. Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: Complications, outcomes, and mortality. Neurocritical Care 2016; 24 (1): 97–103. 5. Малин Д.И., Козырев В.Н., Недува А.А., Равилов Р.С. Злокачественный нейролептический синдром: критерии диагностики и принципы терапии. Соц. и клин. психиатрия. 1997; 7 (1): 76–81. / Malin D.I., Kozyrev V.N., Neduva A.A., Ravilov R.S. Zlokachestvennyi neirolepticheskii sindrom: kriterii diagnostiki i printsipy terapii. Sots. i klin. psikhiatriia. 1997; 7 (1): 76–81. [in Russian] 6. Цыганков Б.Д. Клинико-патогенетические закономерности развития фебрильных приступов шизофрении и система их терапии. М.: Медицина, 1997; с. 56–82. / Tsygankov B.D. Kliniko-patogeneticheskie zakonomernosti razvitiia febril'nykh pristupov shizofrenii i sistema ikh terapii. M.: Meditsina, 1997; s. 56–82. [in Russian] 7. Цыганков Б.Д., Агасарян Э.Т. Анализ эффективности и безопасности современных и классических антипсихотических препаратов. Журн. неврологии и психиатрии им. С.С.Корсакова. 2010; 110 (9): 64–70. / Tsygankov B.D., Agasarian E.T. Analiz effektivnosti i bezopasnosti sovremennykh i klassicheskikh antipsikhoticheskikh preparatov. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2010; 110 (9): 64–70. [in Russian] 8. Ochi S, Kawasoe K, Abe M et al. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation. General Hospital Psychiatry 2011; 33 (6): 640. 9. Horacek J, Bubenikova-Valesova V, Kopecek M et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20 (5): 389–409. 10. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Cur Drug Safety 2009; 4 (1): 84–93. 11. Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry 2012; 24 (2): 155–62. 12. Monte AA, Waksman JC. Chronic olanzapine, serotonin receptors, and subsequent serotonin toxicity. J Clin Psychopharmacology 2010; 30 (5): 628–9. 13. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacotherapy 2008; 42 (9): 1290–7. 14. Uguz F, Sonmez EÖ. Neuroleptic malignant syndrome following combination of sertraline and paroxetine: a case report. General Hospital Psychiatry 2013; 35 (3): 327. 15. Biswas PN, Wilton LV, Pearce GL et al. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacology 2001; 15 (4): 265–71. 16. Murri MB, Bugliani M, Calcagno P et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R&D 2015; 15 (1): 45–62. 17. Johnson V, Bruxner G. Neuroleptic malignant syndrome associated with olanzapine. Australian New Zealand J Psychiatry 1998; 32 (6): 884–6. 18. Stanfield SC, Privette T. Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. J Emergency Med 2000; 19 (4): 355–7. 19. Verma R, Junewar V, Rathaur BPS. An atypical case of neuroleptic malignant syndrome precipitated by valproate. BMJ Case Reports 2014; 2014: bcr2013202578. 20. Sico JJ, Patwa H. Risperidone-induced bulbar palsy-like syndrome. Dysphagia 2011; 26 (3): 340–3. 21. Gambassi G, Capurso S, Tarsitani P et al. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. Aging Clin Experimental Res 2006; 18 (3): 266–70. 22. Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinetics 1993; 24 (2): 161–76. 23. Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first-and second-generation antipsychotics. Brit J Psychiatry 2012; 201 (1): 52–6. 24. Perrault GH, Depoortere R, Morel E et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Experimental Ther 1997; 280 (1): 73–82. 25. Ястребов Д.В. Антипсихотическая терапия с использованием современных инъекционных препаратов длительного выведения. Клинико-фармакологические рекомендации по применению препарата Ксеплион. Рус. мед. журн. 2013; 30: 1610–6. / Iastrebov D.V. Antipsikhoticheskaia terapiia s ispol'zovaniem sovremennykh in"ektsionnykh preparatov dlitel'nogo vyvedeniia. Kliniko-farmakologicheskie rekomendatsii po primeneniiu preparata Kseplion. Rus. med. zhurn. 2013; 30: 1610–6. [in Russian]